Short answer
QuidelOrtho Corp (QDEL) filed its Q1 2026 10-Q quarterly report on May 6, 2026 for the quarter ended Mar 29, 2026. Quarterly revenue was $620M (down 10.5% year over year) with net income of −$92M.
Q1 2026 key financials · XBRL
- Revenue
- $620M
- −10.5% YoY
- Net income
- −$92M
- −622.8% YoY
- Operating margin
- -5.1%
- EPS (diluted)
- −$1.35
- −610.5% YoY
Source: XBRL data from the QuidelOrtho Corp (QDEL) Q1 2026 10-Q on SEC EDGAR. USD.
QuidelOrtho Corp Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $619.8M, down 11% YoY from $692.8M, driven by weaker respiratory products and Joint Business termination
- Cost of sales 57.4% of revenue vs 50.4% YoY
- Best line Immunohematology $138.3M, up 8%; worst Point of Care $112.8M, down 34%
- Cash $140.4M, down $29.4M from December 28, 2025; revolver availability $546.4M
- Headwinds weaker flu season, China pricing uncertainty, Middle East order delays, and tariff-related costs
Risk Factors
- No material changes to previously disclosed risk factors in the Annual Report for fiscal year ended December 28, 2025
- Regulatory and compliance risks carried forward from the Annual Report without quarterly updates
- Operational and competitive risks unchanged from the Annual Report
- Financial risks, including $700.0 million revolving facility and $2.7 billion term loans, unchanged from the Annual Report
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other QuidelOrtho Corp quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.